KB-1225

Tusamitamab

Background

Carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5, also known as CD66e), a cell surface glycoprotein, is weakly expressed in normal epithelial tissues including colon, esophagus, head and neck, stomach, and cervix tissue but is highly expressed in several tumor types including gastrointestinal, lung, and breast. Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells.

Specifications

Catalog Number:
KB-1225
Cell Line Name:
Tusamitamab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CEACAM5
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.S. Decary, P.-F. Berne, C. Nicolazzi, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res, 26 (2020), pp. 6589-6599. 2.S. Hammarstrom. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol, 9 (1999), pp. 67-81.
Please enable JavaScript in your browser to complete this form.